The Combined Performance of ADC, CSF CXC Chemokine Ligand 13, and CSF XXXX in the Diagnosis of Central Nervous System Lymphoma.

@entity1 @entity706 @entity5 @entity11 @entity688
BACKGROUND AND PURPOSE: CXC chemokine ligand 13 and @entity688 have emerged as CSF biomarkers for the diagnosis of @entity706 . Our hypothesis is that the combined use of ADC, @entity688 will result in increased diagnostic performance compared with the use of ADC values alone. MATERIALS AND METHODS: Eighty-seven @entity1 were included in this study, including 43 with @entity706 and 44 without @entity706 (21 metastases, 14 high-grade @entity11 , 9 tumefactive demyelinating lesions) who had undergone CSF proteomic analysis and had a new enhancing mass on brain MR imaging. Average ADC was derived by contouring the contrast-enhancing @entity5 volume. Group means were compared via t tests for average ADC, @entity688 . Receiver operating characteristic analysis was performed for each individual variable. Multiple-variable logistic regression with receiver operating characteristic analysis was performed, and the multiple-variable receiver operating characteristic was compared with single-variable receiver operating characteristics. RESULTS: The average ADC was lower and CSF CXC chemokine ligand 13 and @entity688 values were higher in @entity706 (P < .001). Areas under the curve ranged from 0.739 to 0.832 for single-variable ROC. Multiple-variable logistic regression yielded statistically significant individual effects for all 3 variables in a combined model. Multiple-variable receiver operating characteristics (area under the curve, 0.928) demonstrated statistically significantly superior diagnostic performance compared with the use of single variables alone. CONCLUSIONS: The combined use of ADC, CSF @entity688 results in increased diagnostic performance for the diagnosis of @entity706 . This finding highlights the importance of CSF analysis when the diagnosis of @entity706 is considered on the basis of MR imaging.
